Search

everythinglearnresearchcommunity

for

Search:↓

User shared 126-day progress using Fin/Min/Niz/Microneedling for hair loss. Others discussed microneedling depth, results timeline, frontal coverage, and switching to Dutasteride.

User "manlycoffee" shares 25-month progress using Dutasteride, RU58841, Minoxidil, Microneedling, Nizoral, T/GEL, and fixing vitamin D levels for hair loss. Users discuss sources, experiences, and side effects of treatments.

Triple Hair's TH-16, a product claimed to be more effective than Minoxidil 5%, has been released; it contains melatonin and resveratrol. One user reported success with topical melatonin and dermarolling.

The user experienced worse hair after removing a wig system and has been using Hairband 82 Comfort Flex, Hair Max supplements, dermarolling, and a scalp massager for 4 months without clear results. They are hesitant to use Minoxidil due to shedding concerns and avoid finasteride due to side effects, preferring Saw Palmetto instead.

User shares 4-month hairline progress using minoxidil, finasteride, nizoral, and dermarolling. Others discuss treatment details and express admiration for the results.

User shares 9-month progress using topical Fin/Min formula (10% Min, 0.1% Fin) for hair loss, with significant improvement in crown area. Others discuss experiences, side effects, and application methods for the treatment.

Hair loss progress update: finasteride, minoxidil, dermaroll, nizoral. Dermaroll depth 1.5mm, 3 times a week.

A compounding pharmacist offers affordable topical finasteride foam with Anagain and micro-dose finasteride capsules for hair loss. They provide telehealth services across Canada and private appointments for international patients.

The efficacy of various hair loss treatments, including Finasteride and Dutasteride, with personal anecdotal evidence about potential side effects. It also includes advice to get a male hormone blood panel done before starting treatment, and lifestyle changes to minimize side effects.

Redensyl, which is a topical alternative to Minoxidil for hair loss. It may have advantages such as not making the hair greasy and lasting longer after discontinuing use than minoxidil. There are some positive reports from users, but also some negative ones, so it's unclear how effective this treatment will be in comparison to Minoxidil and other treatments like Finasteride or RU58841.

A 23-year-old with hair loss uses finasteride, minoxidil, and other treatments, considering adding dutasteride due to hairline recession. They seek advice on dutasteride's effectiveness and sourcing.

The conversation discusses Melatonin's potential benefits for AGA and a product called "Asatex" by ASATONA AG. The company was uncooperative when contacted for purchase inquiries.

Taurine shows potential in combating hair loss caused by chemical stress, especially when combined with other treatments like finasteride. Finasteride demonstrated better stress-reducing effects in the study.

Cassiopea claimed that their hair loss treatment, Clascoterone, shows comparable results to finasteride after six months of use. Some users believe Clascoterone could be an additional treatment option for those who do not respond to finasteride.

The conversation is about a new acne treatment cream called Clascoterone Cream 1%, which is the first new mechanism of action for acne in nearly 40 years. One person joked about hoping their face will be as clean as their bald head after using the cream.

RU58841's potential toxicity to cats is uncertain, similar to minoxidil. Caution is advised to prevent accidental exposure to pets.

Minoxidil is extremely toxic to cats, even from residue on surfaces, and can be deadly if they come into contact with it. Switching to oral minoxidil is suggested as a safer alternative for pet owners.

Clascoterone 5% solution showed a 539% improvement in hair count compared to placebo, but the actual increase in hair growth is minimal. Users express skepticism about the effectiveness of hair loss treatments.

The conversation is about receiving a shipment of Koshine, also known as Kintor, which is an anti-androgen treatment for hair loss. The user is eager to try the KX-826 product and observe its effects and any side effects.

Selling KY19382 powder, a novel activator of Wnt/β-catenin signaling, and Kolliphor EL liquid for vehicle formulation. KY19382 is a growth agonist.

The conversation is about selling KY19382 powder, a novel activator of Wnt/β-catenin signaling, and Kolliphor EL liquid for vehicle formulation. The seller offers worldwide shipping.

A user applied the 8T3 product for hair loss, targeting LPP and AGA, and plans to update on its effectiveness. The product uses a saline buffered phosphate vehicle, suitable for those intolerant to ethanolic vehicles.

The conversation is about finding sea salt sprays, volumizing powders, and waxes for hair styling and thickness, specifically available in or shippable to New Zealand. The user seeks affordable options for these hair products.

Calecim (PTT-6) Advanced Hair System is a 6-week hair restoration product using stem cell-derived ingredients to stimulate hair growth. Users are skeptical, calling it overpriced and ineffective, suggesting alternatives like LLLT devices or PRP treatments.

The conversation is about finding a clearnet vendor for clascoterone, also known as Winlevi, for hair loss treatment. The user is seeking recommendations via direct message.

Clascoterone, a topical anti-androgen, is generating interest for potentially fewer systemic side effects. Users are curious about its effectiveness and details like concentration and duration of use.

A user is participating in a phase 3 trial for Clascoterone, a topical acne medication that may stimulate hair growth, and will share results after 6 months. They will have a section of their hair shaved and marked with a tattoo for the study.

SCUBE3 is available online but poses risks like tumor promotion and high costs. Users advise against using it due to health concerns and inefficacy as a standalone treatment.

Clascoterone solution is in Phase III trials for male androgenetic alopecia, with results expected in the second half of 2025. Commercialization is anticipated in about 2-3 years, but there are concerns about delays and market expectations.

The conversation is about making a topical solution from clascoterone powder, with references to using a RU58841 mixing guide for guidance. Concerns about product authenticity and bulk purchase requirements are also discussed.